The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Portfolio Pulse from
Novo Nordisk and United Laboratories International Holdings Limited have signed an exclusive license agreement for UBT251, a triple receptor agonist targeting obesity and type 2 diabetes. The deal includes an upfront payment of $200 million and potential milestone payments up to $1.8 billion. Initial phase 1b trials showed promising results, with patients in the highest dose group experiencing an average weight reduction of 15.1%.
March 24, 2025 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Laboratories (TUL) secures $200M upfront and potential $1.8B in milestone payments by licensing UBT251 to Novo Nordisk for global markets outside Greater China.
The licensing deal provides significant financial upside for United Laboratories and validates their drug development capabilities in the obesity and diabetes treatment space.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Novo Nordisk gains exclusive worldwide rights (excluding Greater China) to UBT251, a promising triple receptor agonist with significant weight loss potential in early trials.
The license agreement represents a strategic expansion of Novo Nordisk's obesity and diabetes treatment portfolio with a promising early-stage drug candidate showing significant weight loss potential.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 95